PATENT COOPERATION TREATY

PCT

ANKOM

2005 -05- 2 0

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference MH/LB 53936	FOR FURTHER see Form PO ACTION as well as, where ap	CT/ISA/220 plicable, item 5 below.
International application No.	International filing date (day month year)	(Earliest) Priority Date (day/month/year)
PCT/SE 2005/000231	21 February 2005	20 February 2004
Applicant		
INDEX PHARMACEUTICALS AB 6	et al	
This international search report has applicant according to Article 18. A	peen prepared by this International Searchicopy is being transmitted to the Internation	ng Authority and is transmitted to the all Bureau.
This international search report consi	ists of a total of sheets.	
It is also accompanied by	a copy of each prior art document cited in	ı this report.
1. Basis of the report	,	
 a. With regard to the language, the in the language in which it was 	ne international search was carried out on t filed, unless otherwise indicated under this	he basis of the international application item.
The international sea furnished to this Aut	arch was carried out on the basis of a trans thority (Rule 23.1(b)).	lation of the international application
b. \prod With regard to any nucleo No. I.	rtide and/or amino acid sequence disclosed in	n the international application, see Box
2. Certain claims were found	d unsearchable (see Box No. II)	,
3. Unity of invention is lacki	ing (see Box No. III)	
4. With regard to the title,		
the text is approved as su		
the text has been establish	ned by this Authority to read as follows:	
		:
5. With regard to the abstract,		
the text is approved as su	bmitted by the applicant.	
the text has been establish	ned, according to Rule 38.2(b), by this Autle month from the date of mailing of this int	nority as it appears in Box No. IV. The ernational search report, submit
6. With regard to the drawings,		
E	published with the abstract is Figure No.	3
as suggested by the a	**	
<u>=</u>	uthority, because the applicant failed to sug	·- •
	uthority, because this figure better characte	rizes the invention.
b. none of the figures is to be	e published with the abstract.	

International application No. PCT/SE 2005/000231

Box No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item1.b of the first sheet)
invention	ard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed in, the international search was carried out on the basis of: of material a sequence listing table(s) related to the sequence listing
b. forma	at of material in written format in computer readable form
c. time	of filing/furnishing contained in the international application as filed filed together with the international application in computer readable form furnished subsequently to this Authority for the purposes of search
OI	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed furnished, the required statements that the information in the subsequent or additional copies is identical to that in the oplication as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Addition	nal comments:

International application No. PCT/SE 2005/000231

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following re-	asons:
1. Claims Nos.: 1-31 because they relate to subject matter not required to be searched by this Authority, namely:	
 Claims Nos.: 1, 3-8, 13-18, 20-23, 27-29, 32-38, 44 because they relate to parts of the international application that do not comply with the prescribed requirements to sextent that no meaningful international search can be carried out, specifically: See extra sheet. 	uch an
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.	4(a).
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
1. As all required additional search fees were timely paid by the applicant, this international search report covers all sclaims.	earchable
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite any additional fee.	payment of
3. As only some of the required additional search fees were timely paid by the applicant, this international search reponly those claims for which fees were paid, specifically claims Nos.:	ort covers
4. No required additional search fees were timely paid by the applicant. Consequently, this international search reporrestricted to the invention first mentioned in the claims, it is covered by claims Nos.:	rt is
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)

Box II.I.

Claims 1-31 relate to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic methods /Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compositions.

Box II.2

Present claims 1-8, 13-23, 27-29, 32-38, 44 relate to a compound defined by reference to a desirable characteristic or property, namely "an NF-kappaBp65 inhibitor". The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds described in claims 9-12, 24-26, 30, 31, 40-43, 45, 46.

Further, the search has covered the general aspects of the invention to some extent, although it lacks the necessary precision in the definition of the subject matter. Consequently, the search for the general concept of "an NF-kappaBp65 inhibitor" will retrieve a pertinent document only if this concept is described in general terms in a reference. Specific solutions previously known and falling under the general concept - but failing to mention this fact - are likely not to be revealed in such a search.

International application No.

PCT/SE 2005/000231

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12N 15/11, A61K 48/00, A61K 38/00, A61P 9/10
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12N, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X Journal of cerebral flow and Metabolism 1 - 462001, Vol.21, Nr2;Chiung-Ying Huang et al;

"SOD 1 Down-regulates Nf-kappaB and c Myc expression

in mice after transient focal cerebral ischemia" abstract, page 165-169 X WO 03041640 A2 (THE GENERAL HOSPITAL CORPORATION), 1-46 22 May 2003 (22.05.2003), page 2, line 1 - line 20; page 5, line 16; page 6, line 16

X	Further documents are listed in the continuation of B	ox C.	See patent family annex.
*	Special categories of cited documents:	#T"	later document published after the international filing date or priority
"A"	document defining the general state of the art which is not considere	d	date and not in conflict with the application but cited to understand

- to be of particular relevance the principle or theory underlying the invention
- "E" earlier application or patent but published on or after the international filing date "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other
- document of particular relevance: the claimed invention cannot be special reason (as specified) considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "O" document referring to an oral disclosure, use, exhibition or other
 - document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family

Telephone No. +46 8 782 25 00

Date of the actual completion of the international search Date of mailing of the international search report **1 9 -05-** 2005 10 May 2005 Name and mailing address of the ISA/ Authorized officer **Swedish Patent Office** Box 5055, S-102 42 STOCKHOLM Malin Söderman/MP

Form PCT/ISA/210 (second sheet) (January 2004)

Facsimile No. +46 8 666 02 86

International application No.
PCT/SE 2005/000231

		PC1/SE 2005	7000231
C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the rele	want passages	Relevant to claim No
х	WO 9747325 A1 (KAROLINSKA INNOVATIONS AB), 18 December 1997 (18.12.1997), page 12, line 1 - line 15, abstract		2,9-12,24-26
A			1,3-8,13-23, 27-39,44-46
x	WO 03070918 A2 (RIBOZYME PHARMACEUTICALS, INCORPORATED), 28 August 2003 (28.08.2003 page 135, SEQ ID NO 119, SEQ ID NO 120),	30,31,45,46
A			1-29,32-44
A	US 20010002391 A1 (STEPHEN BRAND ET AL), 31 M 2001 (31.05.2001), claims 1,21,22	lay	1-46
A	US 5994402 A (ORI D. ROTSTEIN ET AL), 30 November 1999 (30.11.1999), claims 1-	·28	1-46
			
			
orm Pornito	A ₂ 210 (continuation of second sheet) (January 2004)		

Information on patent family members

01/04/2005

International application No. PCT/SE 2005/000231

WO	 A2	22/05/2003	US	20030118578	A 26/06/2003
WO	 A1	18/12/1997	AU SE	3200197 9602300 I	A 07/01/1998

Form PCT/ISA/210 (patent family annex) (January 2004)

Information on patent family members

01/04/2005

International application No.
PCT/SE 2005/000231

	·					
WO	03070918	A2	28/08/2003	AU	2003207708 A	00/00/0000
				AU	2003210895 A	
				AU	2003211058 A	
				AU	2003211082 A	00/00/0000
				AU	2003213005 A	
				AU	2003213054 A	
				AU	2003213057 A	- · · · · · · · · · · · · · · · · · · ·
				AU	2003213090 A	
				AU	2003213119 A	
				AU	2003213163 A	
				AU	2003213203 A	
				AU	2003215161 A	
				AU	2003215203 A	
				AU Au	2003215345 A 2003216245 A	
				AU	2003216255 A	
				AU	2003216265 A	
				AU	2003216263 A	
				AU	2003216315 A	
				AU	2003216323 A	
				ΑŬ	2003216324 A	
				AU	2003217550 A	
				AU	2003217594 A	00/00/0000
				AU	2003219712 A	00/00/0000
				AU	2003219751 A	00/00/0000
				AU	2003219781 A	
				AU	2003219817 A	
				AU	2003219818 A	
				AU	2003219833 A	• •
				AU	2003220136 A	
				AU	2003221258 A	
				AU Ca	2003247204 A 2455447 A	
				CA	2455506 A	
				CA	2456444 A	
				CA	2457528 A	
				CA	2459532 A	
				CA	2463595 A	
				CA	2471421 A	
				CA	2476112 A	
				CA	2476394 A	
				CA	2477014 A	28/08/2003
				EP	1423404 A	• •
				EP	1423406 A	· -
				EP	1430157 A	
				EP	1432724 A	
				EP	1432725 A	
				EP	1436314 A	· ·
				EP	1442143 A	
				EP Ep	1448580 A	
				EP	1448590 A 1458741 A	- ·
				EP	1458741 A 1463842 A	
				EP	1465910 A	

				ĒΡ	1470256 A	

Information on patent family members

01/04/2005

International application No. PCT/SE 2005/000231

WO 03070918 A2 28/08/2003 EP 1470257 A 27/10/2004 03/11/2004 ΕP 1472265 A ΕP 1472267 A 03/11/2004 EP 1472269 A 03/11/2004 EP 1474433 A 10/11/2004 EP 1476457 A 17/11/2004 ΕP 1476458 A 17/11/2004 EP 1476459 A 17/11/2004 EP 1476574 A 17/11/2004 EP 1478730 A 24/11/2004 EP 1495041 A 12/01/2005 EP 1499628 A 26/01/2005 EP 1499631 A 26/01/2005 EP 1501853 A 02/02/2005 0404898 D GB 00/00/0000 GB 0404907 D 00/00/0000 GB 0404912 D 00/00/0000 GB 0405023 D 00/00/0000 GB 0406022 D 00/00/0000 GB 0427814 D 00/00/0000 GB 0427955 D 00/00/0000 GB 2396155 A 16/06/2004 GB 2396616 A 30/06/2004 GB 2396864 A,B 07/07/2004 GB 2397062 A 14/07/2004 GB 2397818 A,B 04/08/2004 US 20030170891 A 11/09/2003 US 20030190635 A 09/10/2003 US 20030206887 A 06/11/2003 US 08/01/2004 20040006035 A US 20040110296 A 10/06/2004 US 20040127446 A 01/07/2004 US 20040142895 A 22/07/2004 US 20040192626 A 30/09/2004 US 20040198682 A 07/10/2004 20040209831 A US 21/10/2004 US 20040209832 A 21/10/2004 US 20040219671 A 04/11/2004 US 20040249178 A 09/12/2004 US 20050014172 A 20/01/2005 US 20050020525 A 27/01/2005 US 20050032733 A 10/02/2005 US 20050048529 A 03/03/2005 US 20050054596 A 10/03/2005 US 20050054598 A 10/03/2005 WO 03070193 A 28/08/2003 WO 28/08/2003 03070197 A 03070742 A WO 28/08/2003 WO 03070743 A 28/08/2003 WO 03070744 A 28/08/2003 WO 03070750 A 28/08/2003 WO 03070881 A 28/08/2003 WO 03070884 A 28/08/2003 WO 03070885 A 28/08/2003 WO 03070886 A 28/08/2003

Information on patent family members

01/04/2005

International application No.

PCT/SE 2005/000231

WO	03070918	A2	28/08/2003	WO	03070887 A	28/08/2003
πU	03070318	nL	20/00/2003	WO	03070887 A,I	
				WO	03070895 A	28/08/2003
				WO	03070896 A	28/08/2003
				WO	03070897 A	28/08/2003
				WO	03070903 A	28/08/2003
				WO	03070910 A	28/08/2003
				WO	03070911 A	28/08/2003
				WO	03070912 A	28/08/2003
				WO	03070914 A	28/08/2003
				WO	03070917 A	28/08/2003
				WO	03070966 A	28/08/2003
				WO	03070968 A	28/08/2003
				WO	03070969 A	28/08/2003
				WO	03070970 A	28/08/2003
				WO	03070972 A	28/08/2003
				WO	03070983 A	28/08/2003
				WO	03072590 A	04/09/2003
				WO	03072704 A 03072705 A	04/09/2003 04/09/2003
				WO	03072705 A 03074654 A	12/09/2003
				WO WO	03074634 A 03106476 A	24/12/2003
				AU	2003245512 A	00/00/0000
				ÜS	20040236482 A	25/11/2004
				WO	03102131 A	11/12/2003
				WO	2004103791 A	02/12/2004
us Us	20010002391	A1	31/05/2001	 US	6271199 B	07/08/2001
		•••	,,	ÜS	20010053760 A	20/12/2001
				US	20030069189 A	10/04/2003
				AT	240113 T	15/05/2003
				AU	741802 B	13/12/2001
				AU	6171998 A	08/09/1998
				CA	2281224 A	20/08/1998
				CN	1159061 C	28/07/2004
				CN	1250376 A,	
				DE	69814618 D,	
				EP	0979096 A,	
				ES	2196547 T	16/12/2003
				HK	1025266 A	00/00/0000
				IL	131410 D	00/00/0000
				JP	2001511814 T	14/08/2001
				NO	993935 A	04/10/1999
				NZ	337364 A	29/06/2001
				PT	979096 T	30/09/2003
				WO	9835691 A	20/08/1998
US	5994402	Α	30/11/1999	CA	2197058 A	06/12/1997